Pradelli, Lorenzo, et al. “Cost‑effectiveness Analysis of Apixaban Versus Other NOACs for the Prevention of Stroke in Italian Atrial Fibrillation Patients”. Farmeconomia. Health Economics and Therapeutic Pathways, vol. 15, no. 4, Dec. 2014, pp. 101-12, doi:10.7175/fe.v15i4.971.